ACTC in trouble

ACTC announced today that the company has been named as a defendant in a civil action brought by the SEC related to transactions involving the sale and issuance of the company's securities. That is just great down we go, share price is down at 0.0692 on over 13.8 million shares. The three month avg. volume is 6.6 million shares. The only good thing is that the people, that did this are gone, not running the company. I still feel the Phase 1/2 trials will save them. But it will be a hard and painful ride.

Geron the rumor on Yahoo message board is they are looking at an acquisition. I don't see how or why, but stranger thing have happen. Geron is up a penny.

Good luck in this rigged casino,

Geron new low

Geron hit a new 52 week low of $1.31 and closed at $1.32 on 903,831 shares. The three month avg. volume is 688,366. With no good news and fear creeping into the market we will go lower.

ACTC was down a little on almost no volume of 1.7 million shares the three month avg. is 6.6 million shares. Market waiting for reverse split. No one wants to buy before that and there must be more good news on the Phase 1//2 trials. If not we will go lower.

AAPL up $6.90 to $579.17. The market is going down, people want to go down owning the best. Volume was 18.9 million shares. Three month avg. is 23.8 million shares.

Good luck in this rigged casino,

Geron CEO doubles office space

That's the rumor on Yahoo's message broad. If true, something big is about to happen. I hope it's for the good. Geron closed at $1.40 on only 487,408 shares. Three month avg. volume is 698,677 shares. No volume, no price move, no news.

AAPL closed at $572.27 on 13.6 million shares. Three month avg. volume is 24 million shares. AAPL will be going higher.

ACTC closed at 0.07999 on 2 million shares. The three month avg. volume is 6.8 million shares. Waiting for the reverse split. News on Phase 1/2 trials will move the price up if as good as last news report.

Good luck in this rigged casino,

Geron moving forward

I listened to Geron Annual Shareholders Meeting. The company must have good results from the 6 Phase two trials. Four of the trials deal with imetelstat that target the telomerase to arrest cancer cell proliferation. Those Phase two results will be given Dec 2012. The last two, GRN1005 is designed to cross the blood brain barrier,
those two will have results 2Q 2013. Without some kind of good results Geron is done.

Good luck in this rigged casino,

ACTCs science and patents worth billions?

ACTC science and portfolio of patents are likely worth billions. We need the reverse split so institutional investors can make investments. Over time 12 to 24 months if positive results are reinforced by all the new enrolled patients to be injected, the share price will more than quadruple [that's the reverse split price, what ever that price is]. ACTC closed up a little at 0.08 on 1.5 million shares. The three month avg. volume is 6.8 million shares.
Geron closed up 3 cents at $1.42 on only 369,563 shares. The three month avg. volume 698,677 shares. With no news, there's no interest in this company. That said the share price will go lower until there is good news, THE DEAL or the 6 Phase two trials.
AAPL down $3.03 to closed at $562.29 on 11.7 million shares. The three month avg. volume is 24 million shares. Still think it goes higher soon.

Good luck in this rigged casino,

ACTC up a little Geron flat

Looks like AAPL will not hit $590. If you look back on my pass blogs. If you had bet against me you would be a lot richer then me. I don't rewrite my blogs, you can look back and see all my mistakes, which are many.

I still feel ACTC will make me rich. With my track record I would put it at 10% of happening.

I still feel Geron will make me rich. Again I would put it at 15% of happening.

AAPL will go up I put that at 95%,  it will happen.

Always remember you can lose all your money in this rigged casino,

AAPL up big Geron up a little

Feeling better, AAPL closed up $13.59 at $570.56. Still say we hit $590 this week. Volume was 20.5 million shares, three month avg. 24 million shares.
Geron closed at $1.41 on only 334,768 shares. Three month avg volume is 711,864. This waiting is a killer. I have over 13,000 shares [avg. cost $3.15] need to unload 5,000 shares. Hoping for a great deal with a partner. If the 6 Phase 2 trials have good results we will double in price, maybe much more if a sugar daddy comes in and partners.
ACTC closed down just a little at 0.0819  on volume of 2.3 million shares. Three month avg. volume is 7 million. Preliminary results on Phase 1/2 trials are good, we should go higher.

God luck in this rigged casino,

ACTC and Geron Down

ACTC should have move higher on the preliminary results of there Phase 1/2 trials but the market does not like the reverse split that will be coming, does not like the balance sheet. I would buy more shares but I'm all in AAPL.
I thought AAPL was going up to stay, at $573.88 I was very happy[my avg. cost is $572], then down it went to close at $556.97, down $4.31 on 24.8 million shares. Three month avg. volume is 24 million shares. AAPL is still the best company out there.

Geron closed down a penny at $1.39 on only 444,820 shares. Three month avg. volume 711,864.

Good luck in this rigged casino,

ACTC Preliminary Results

This is from the London presentation. Embryonic stem cell trials for macular degeneration. Structural evidence confirmed cells had attached and persisted. No signs of hyperproliferation, abnormal growth or rejection. Anatomical evidence of hESC-RPE survival and engraftment. Clinically increased pigmentation within the bed of the transplant. SMD patient: BCVA improved from hand motions to 20/800 and improved from 0 to 5 letters on the ETDRS visual acuity chart. Nine Month Follow-up: Visual acuity remain stable for both patients: SMD Patient continues to show improvement. Similar trends observed for latest AMD and SMD patients.
You can get the rest of the London presentation on ACTC website.
This is great news ACTC closed up at 0.089. The volume was not great only 6.3 million shares. Should have been 12 million at least with that news. We should up higher.

AAPL finally up big to close at $561.28 SHOULD go higher $590 this week.

Geron closed up a little at $1.40 on 895,325 shares, three month avg. volume 722,408 shares. No news.

Good luck in this rigged casino,

ACTC Moving Up

Advanced Cell Technology (ACTC.OB): Friday's ten percent price spike has shares of Advanced Cell Technology on the watch list moving into the new trading week. It's also worth noting that the company's CEO, Gary Rabin, will be presenting at the World Stem Cells and Regenerative Medicine Conference in London this week.
Mr. Rabin will offer updates on three ongoing clinical studies testing ACT's stem cell therapy in the treatment of severe blindness in a presentation titled, “Successes and ongoing advancements of human clinical trials for the treatment of AMD & Stargardt’s Disease.”
Shares of ACTC have dropped since the announcement of intent to conduct a reverse stock split, a move that comes as the logical next step in the company's development, and if the RS is accompanied by a move to a larger trading board, then it could provide an instant credibility boost to those who won't touch OTCBB stocks.
The CEO presentation may also draw additional attention to the stock, which posted impressive gains on Friday, considering the overall down market

ACTC looks good for now.

Good luck in this rigged casino,

ACTC up 13%

ACTC up on the news of presentation in London on May 21st. I still love the title [see Thurs blog]. ACTC closed at 0.0824 on 6.4 million shares. Three month avg, volume is 7.2 million shares.

Geron closed down 4 cents at $1.37 on 926,183 shares. Three month avg. volume is 727,608 shares. Nothing good is happening, share price will go lower, without any good news.

AAPL finally closed up, just a little today at $530.38 on 26.2 million shares. Three month avg. volume is 24 million shares.

Market looks like it well go down a little more, and then a little more and so on and so on.

Good luck in this rigged casino,

ACTC will Present in London May 21st

MARLBOROUGH, Mass., May 18, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will be presenting at the World Stem Cells and Regenerative Medicine Conference, May 21-23, in London.
Mr. Rabin's presentation, titled "Successes and ongoing advancements of human clinical trials for the treatment of AMD & Stargardt's Disease," will be given on Monday, May 21 at 5:05 p.m. BST (London time). Mr. Rabin will provide an update on ACT's three ongoing human clinical trials in the U.S. and E.U. for Dry Age-Related Macular Degeneration (Dry AMD) and Stargardt's Macular Dystrophy (SMD).
ACT recently announced Data and Safety Monitoring Board (DSMB) approval to move forward with enrollment and treatment of additional patients with SMD in its U.S. SMD trial, and to treat the final two patients to round out the initial dosing arm in its European trial. All three of the company's ongoing clinical trials use human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.
About SMD, Dry AMD and Degenerative Diseases of the Retina
Stargardt's Macular Dystrophy (SMD) is one of the most common forms of macular degeneration in the world. SMD causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium or RPE cell layer.
Degenerative diseases of the retina are among the most common causes of untreatable blindness in the world. As many as thirty million people in the United States and Europe suffer from macular degeneration, which represents a $25-30 billion worldwide market that has yet to be effectively addressed. Approximately 10% of people ages 66 to 74 will have symptoms of macular degeneration, the vast majority the "dry" form of AMD -- which is currently untreatable. The prevalence increases to 30% in patients 75 to 85 years of age

This should drive the share price up. I love the title of presentation. If they have proof this is working, up we go. They still need a partner to pay for the next round of trials.

Good luck in this rigged casino,

Geron No News from Shareholder Meeting

I missed the webcast, was out yard sailing. Will listen Friday. Checked the Yahoo message board, not happy with meeting, no answers about deal, nothing news. Volume and share price say it all, closed down 5 cent  at $1.41, on 590,969 shares. The three month avg. volume is 740,467 shares.

ACTC up a little, closed at 0.0725 on 4.9 million shares, three month avg. volume is 7.2 million shares. No news.

AAPL down again to close at $530.12 on 25.6 million shares, three month avg. volume is 23.9 million share. If I had the money I would buy a few more shares. Can't go down forever.

Good luck in this rigged casino,

Geron Annual Shareholder Meeting May 17 at 8AM PT

Geron Annual Shareholder Meeting today at 8AM PT. Will be webcast. I will be listening. Hoping for good news but share price and volume say no.

AAPL down again.

Good luck in this rigged casino,

Waiting for end of 2012 GERON

Two randomized Phase 2 clinical trials of imetelstat in solid tumors continued enrollment throughout 2011: a study in patients with metastatic breast cancer (B014) and a study in patients with advanced non-small cell lung cancer (B012). These two trials require that a sufficient number of progression events occur in order to perform the planned data analyses. Geron anticipates an accrual of events that will allow the company to report top-line data from these two Phase 2 trials by the end of 2012.
◦Two single-arm Phase 2 trials of imetelstat in hematological malignancies were initiated in the first quarter of 2011 to evaluate the impact of the drug on cancer progenitor cells: a study in patients with essential thrombocythemia (B015) and an exploratory study in patients with multiple myeloma (B013). Top-line data from these two trials are expected to be available by the end of 2012.

http://www.reuters.com/article/2012/03/0...

Positive results mean: double/triple

Geron needs good results to survive. Closed up 1 cent at $1.46 on 753,767 shares. Three month avg. volume is 760,605 shares. 

ACTC closed down just a little at 0.072 on 2.6 million shares. Three month avg. volume is 24 million shares.

AAPL still going down closed at $546.08. Will buy more but will wait.

Good luck in this rigged casino,

AAPL down again after I bought

I added more AAPL shares at $562.70 and it went down more,[what a surprise] to close at $553.17, on 17 million shares. Three month avg. volume 24.5 million shares. Will add more, but will wait.

Geron closed flat at $1.45 a share, volume was very low at 288,703 shares. Three month avg. volume is 775,652. Beating the same drum, we need a DEAL, good results from the 6 Phase 2 trials.

ACTC up just a little closing at 0.073 on 3.6 million shares. Three month avg. volume is 7.7 million share. Roll the dice and see what comes up in a few months.

Good luck in this rigged casino,

AAPL ACTC GERN all down

AAPL hit my bid today at $562.70 on it closed at $558.22 on 12.6 million shares. Three month avg. volume 24.6 million. Will buy more, still have 72 more shares to go [goal is 100 shares].

ACTC down, down, down closed at 0.067 on 5.9 million shares. Three month avg. volume is 7.6 million shares. I still believe in this company. I still could lose all my money.

Geron closed down at $1.45 on 577,470 shares. Three month avg. volume is 783,502 shares. Nothing, no news, no volume, only wait and hope the price stops falling before the DEAL.

Good luck in this rigged casino,

Down, AAPL didn't hit my bid

AAPL didn't hit my bid Friday so maybe Monday. AAPL closed down $3.81 at $566.71 on 14.3 million shares. Three month avg. volume is 24.6 million shares, so there's no big sell off. With oil down under $100 at $95.57 we should have a little more money to buy AAPL products, if oil can hit $85-$90 we should have a good Xmas. This is the best company out there.

ACTC down 5.79% at 0.0716 on 11.7 million shares, that is bad, the three month avg. is 7.8 million shares, meaning folks are selling off [jumping ship] and we will go lower, without any good news. This company is a roll of the dice. Looking like snake eyes for now.

Geron down 5 cents at $1.49 on only 447,578 shares. The three month avg. is 778,056. No sell off, folks just don't care about Geron. We still may go lower. Need good news, the DEAL, good results from the 6 Phase 2 trials.

Good luck in this rigged casino.

Still Can't Cut a Break with AAPL

I added more AAPL at $573.53 and then more at $569.97. Then what happen JPM stated it suffered a trading loss of at least $2 billion [maybe $4+ billion] from a failed hedging strategy. Afterhours AAPL was down to $568. JPM will drag the whole market down Friday. I will buy a few more AAPL shares early Friday.    With my luck AAPL will somehow go bankrupt.

Geron closed up 6 cents at $1.54 on very light volume of 365,575. The three month avg, volume is 780,848 shares. Again it's just sit and wait, for the deal [if any] good results [hoping for] on the 6 Phase 2 trials.

I repeat now more than ever, GOOD LUCK IN THIS RIGGED CASINO,

Geron and ACTC down

Geron closed down a little at $1.485 on 692,994 shares. Three month volume avg. is 783,221 shares. We need good news on a deal or the 6 Phase 2 trials. Without that we will go lower.

ACTC, no one liked the earnings webcast we closed down under 8 cents at 0.0790 on 6.9 million shares. The three month avg. volume is 7.9 million shares. If what the CEO reports is true about the Phase 1/2 trials we should be higher soon. If ACTC can't prove the vision improvement then it's out of business.  IMO they will prove it and we will be rich. Maybe.

Good good in this rigged casino,

ACTC Trials Showing Improvement

I listened to the earnings call. ACTC has money to last 1 year tops. Then they must partner or rise more money  by ?  So they lost $5.4 million compared to a loss from operations of $4.8 million in the 2011 first quarter. ACTC stated that vision has improved and has stayed at that level. That is great news. ACTC will be filing for uplift to NASDAQ in the next few days. That is good news. ACTC is down just a little at 0.08. This company is a roll of the dice. The trial must show proof of improved vision. IMO they will.

Good luck in this rigged casino,

ACTC Earnings call Wednesday May 9 at 9AM EDT

ACTC earnings call Wednesday, May 9th at 9AM EDT. Will discuss 2012 first quarter results for the period ended March 31, 2012 and provide a corporate update. Will be streamed via webcast. ACTC closed at 0.0805 on 2.4 million shares. Three month avg. volume is 8.7 million shares. Will be listening to webcast.

Geron closed up a penny at $1.52. on only 309,725 shares. The three month avg volume is 794,769 shares. Waiting for news on the stem cell deal if any.

Three days for money to clear and will buy more AAPL.

Good luck in this rigged casino,

Can't cut a break on AAPL

I have 9 shares of AAPL slowly working my way up to 100 shares and then will sell a covered call. Right after I bought 1 share of AAPL it went down 15 points I then bought 8 more shares and it went down 20 more points. Afraid if I buy more it will go down 30 more points. I will buy more. It's the best company out there.

Geron closed down 4 cent at $1.51 on 604,131 shares. Three month avg. is 815,038 shares.  Again with no good news, we stay here and may go lower. The stem cell deal should come soon by July I hope. The 4 Phase 2 trial will have results by the end of this year. If there is no deal and poor results from trials Geron will trade in the pennies.

ACTC closed down a little at 0.0802 on 3.3 million shares. The three month avg volume is 8.3 shares. With more good results from Phase 1/2 trial we should hit 20 cent, with a joint venture we should hit $1.00.

Again both Geron and ACTC are a roll of the dice. Remember you can lose all your money in any company. I'm doing a good job doing just that.

Good luck in this rigged casino,

Non Small Cell Lung Cancer Trial Enrollment Completed

Geron completed planned enrollment of it's randomized Phase 2 clinical trial of imetelstat, a telomerace inhibitor, for patients with advanced non-small cell lung cancer.

We need positive news before years end, a partnering or selling of Geron's stem cell properties. That would produce an easy double in share price, maybe more. Will it happen, I think IMO soon, by July. With no real good news we stay at this level, and may go lower. Geron closed down one cent at $1.55 on 854,677 shares. The avg three month volume is 824,529.


Bought 7 more AAPL, 91 more to go, it's going to take a while.


Good luck in this rigged casino,

Good webcast Geron

I listened to the 1Q 2012 Geron earnings conference call. Things are moving froward. Two of the Phase II trials have completed enrollment that is great news. Four more to go. Four Phase II trials will have results by the end of Dec 2012. Two Phase II trials will have results by Q2 of 2013. Chip stated they are in talks with people on selling stem cell business. Geron lost 15 cents this last Q.  Burned 20.2 million dollars this last Q. Geron has money to last 2 years, maybe. I bought 100 more shares at $1.54.

Geron closed down 7 cents at $1.56 on 980,000 shares. Three month avg. volume is 826,500 shares.

Good luck is this rigged casino,

Geron down Webcast today at 4:30PM 1Q Earnings

Geron down 5 cents at $1.58 on very little volume. I hope Chip has some good news today.

Added to my ACTC shares at 0.081.

Both companies are a roll of the dice. Remember you can lose all your money in any company.

Also bought one share of AAPL at $579.78. I will be adding AAPL slowly, working up to 100 shares. I have 98 more shares to go. When I hit 100 will sell a covered call.

Good luck in this rigged casino,

Webcast Q1 2012 Geron Earnings Conference Call

Q1 2012 Geron earnings conference call May 2 at 4:30PM. I will be listening, hoping for some positive news.
If you want to listen, go to Geron's website, click Investor Relations, click Events, look under Upcoming Investor Events and click Q1 2012 Earnings Conference Call.

Mr Earp resigned from his position as the company's Chief Legal Officer. Rumor is ViaCyte Lawyers were at Geron Corporate office Monday. They were doing the video deposition of Dr. Coleman. Mr. Earp is leaving after June he was staying until Geron/ViaCyte case is done, in June. Maybe ViaCyte/JNJ and Geron have come to an agreement to do a deal.

Geron closed down 4.5 cents at $1.63 on 533,535 shares. Three month avg volume is 835,484 shares. Going by the share price and volume the earnings conference call will be more of the same. I hope I'm wrong.

Good luck in this rigged casino,